Coya Therapeutics (COYA) Enterprise Value (2021 - 2026)
Coya Therapeutics (COYA) posted Enterprise Value of -$50.7 million for Q1 2026, down 8.33% sequentially from -$46.8 million in Q4 2025, and down 42.76% YoY from -$88.6 million in Q1 2025.
Coya Therapeutics (COYA) Enterprise Value (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Enterprise Value for 6 years, with the latest figure at -$50.7 million in Q1 2026.
- Quarterly Enterprise Value fell 42.76% year-over-year to -$50.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.7 million (down 42.76% YoY) and the FY2025 annual result came in at -$46.8 million, down 22.13% from the prior year.
- Enterprise Value slipped to -$50.7 million in Q1 2026 per COYA's latest filing, from -$46.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.9 million in Q4 2022 and troughed at -$50.7 million in Q1 2026.
- A 5-year average of -$29.4 million and a median of -$31.8 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value tumbled 449.86% in 2023, then climbed 18.7% in 2025.
- Over 5 years, Enterprise Value stood at -$5.9 million in 2022, then sank by 449.86% to -$32.6 million in 2023, then slipped by 17.51% to -$38.3 million in 2024, then dropped by 22.13% to -$46.8 million in 2025, then dropped by 8.33% to -$50.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$50.7 million, -$46.8 million, and -$28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | Coya Therapeutics | 113.06 Mn | 69.86 Mn | - | -43.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.20 Mn |
| Mar 31, 2026 | -50.72 Mn |
| Dec 31, 2025 | -46.82 Mn |
| Sep 30, 2025 | -28.13 Mn |
| Jun 30, 2025 | -29.76 Mn |
| Mar 31, 2025 | -35.53 Mn |
| Dec 31, 2024 | -38.34 Mn |
| Sep 30, 2024 | -31.06 Mn |
| Jun 30, 2024 | -36.60 Mn |
| Mar 31, 2024 | -35.99 Mn |
| Dec 31, 2023 | -32.63 Mn |
| Sep 30, 2023 | -10.89 Mn |
| Jun 30, 2023 | -13.10 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -5.93 Mn |
| Dec 31, 2021 | -4.34 Mn |